Published in Radiology on July 01, 1994
Proteomic contributions to personalized cancer care. Mol Cell Proteomics (2008) 1.46
Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer (2007) 1.30
Ovarian cancer: the clinical role of US, CT, and MRI. Eur Radiol (2003) 1.12
Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer. Br J Cancer (2012) 0.93
Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer (2004) 0.89
Contrast-enhanced ultrasound in ovarian tumors - diagnostic parameters: method presentation and initial experience. Clujul Med (2013) 0.78
The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health (1995) 2.43
Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene (2008) 2.31
Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. Cancer Epidemiol Biomarkers Prev (2001) 2.12
A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci U S A (1990) 2.11
Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol (1999) 1.91
An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol (1981) 1.80
Postsplenectomy sepsis and mortality in adults. JAMA (1982) 1.70
Small bowel motility in diabetics. Am J Dig Dis (1969) 1.64
Psychosocial benefits of a cancer support group. Cancer (1986) 1.62
Advanced squamous cell carcinoma of the cervix with recent normal Papanicolaou tests. Lancet (1980) 1.61
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med (1987) 1.60
A case-control study of cancer of the endometrium. Am J Epidemiol (1982) 1.50
Adenocarcinoma in situ of the cervix: management and outcome. Gynecol Oncol (1999) 1.45
Novel embryonic genes are preferentially expressed by autonomously replicating rat embryonic and neointimal smooth muscle cells. Circ Res (2000) 1.45
Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol (1993) 1.33
Ovarian cancer staging: does it require a gynecologic oncologist? Gynecol Oncol (1992) 1.25
Treatment of ovarian stromal tumors. Am J Obstet Gynecol (1976) 1.22
Distribution of estrogen receptor-beta-like immunoreactivity in rat forebrain. Neuroendocrinology (1997) 1.21
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer (2009) 1.20
Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev (1999) 1.19
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene (2011) 1.12
Allelic loss in ovarian cancer. Int J Cancer (1993) 1.12
Circulating tumor markers in the monitoring of gynecologic malignancies. Cancer (1987) 1.11
Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays. Oncogene (2012) 1.10
Associations between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States). Cancer Causes Control (2001) 1.10
Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers. Cancer Res (1988) 1.08
Pretreatment prognostic factors in carcinoma of the uterine cervix: a multivariable analysis of the effect of age, stage, histology and blood counts on survival. Int J Radiat Oncol Biol Phys (1983) 1.06
Developmentally timed expression of an embryonic growth phenotype in vascular smooth muscle cells. Circ Res (1994) 1.05
Circulating levels of CSF-1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms. Int J Radiat Oncol Biol Phys (1989) 1.04
Urinary gonadotropin fragment, a new tumor marker. I. Assay development and cancer specificity. Gynecol Oncol (1990) 1.03
Pelvic masses in pregnancy: MR imaging. Radiology (1990) 1.02
The RNA-binding protein La contributes to cell proliferation and CCND1 expression. Oncogene (2010) 1.02
Uterine papillary serous carcinoma. Obstet Gynecol (1987) 1.01
Structural organization of the Amy locus in seven strains of Drosophila melanogaster. Nucleic Acids Res (1986) 1.01
Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: Clinical and histologic correlations. Am J Clin Pathol (1990) 1.00
Stage IIIA carcinoma of the uterine cervix. Gynecol Oncol (1986) 1.00
High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas. Int J Radiat Oncol Biol Phys (1988) 1.00
Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol Oncol (1990) 0.99
Rapidly progressive squamous cell carcinoma of the cervix coexisting with human immunodeficiency virus infection: clinical opinion. Gynecol Oncol (1991) 0.99
Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer (2013) 0.99
Obstetric and nonmalignant gynecologic bleeding: treatment with angiographic embolization. Radiology (1987) 0.98
Epithelial carcinoma of the ovary: current strategies. Ann Intern Med (1981) 0.98
High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol (1993) 0.97
Carcinosarcoma of the ovary. Int J Gynecol Cancer (2007) 0.96
Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol (1988) 0.96
Steroid-receptor proteins in nonepithelial malignancies of the ovary. Gynecol Oncol (1983) 0.95
Trisomy 12 and K-ras-2 amplification in human ovarian tumors. Int J Cancer (1991) 0.94
Urinary gonadotropin fragment, a new tumor marker. II. Differentiating a benign from a malignant pelvic mass. Gynecol Oncol (1990) 0.94
Frequent loss of heterozygosity on chromosomes Xp and 13q in human ovarian cancer. Int J Cancer (1992) 0.94
Radiation treatment of FIGO stage IVA carcinoma of the cervix. Gynecol Oncol (1989) 0.94
Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival. Am J Obstet Gynecol (1993) 0.93
Second-look operations in ovarian cancer. Am J Obstet Gynecol (1980) 0.93
Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol (1982) 0.93
Extramammary Paget's disease of the vulva. Gynecol Oncol (1995) 0.91
Endometrial stromal sarcoma: a clinicopathologic study of 11 cases with determination of estrogen and progestin receptor levels in three tumors. Gynecol Oncol (1987) 0.91
Structural organization of the alpha-amylase gene locus in Drosophila melanogaster and Drosophila miranda. Isozymes Curr Top Biol Med Res (1987) 0.91
Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol (2000) 0.90
Allele loss at the retinoblastoma locus in human ovarian cancer. J Natl Cancer Inst (1991) 0.90
Psychosocial reactions to the diagnosis of gynecologic cancer. Obstet Gynecol (1983) 0.89
Control of arterial hemorrhage using percutaneous arterial catheter techniques in patients with gynecologic malignancies. Gynecol Oncol (1975) 0.89
Fallopian tube carcinoma. Int J Radiat Oncol Biol Phys (1985) 0.88
Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. Br J Cancer (2009) 0.88
Leiomyosarcomas: clinical presentation. Am J Obstet Gynecol (1993) 0.87
Magnesium homeostasis following chemotherapy with cisplatin: a prospective study. Am J Obstet Gynecol (1985) 0.87
Trisomy 12 in benign fibroma and granulosa cell tumor of the ovary. Gynecol Oncol (1990) 0.87
Saliva and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol (1990) 0.87
Percutaneous endoscopic gastrostomy for gastric decompression in metastatic gynecologic malignancies. Surg Gynecol Obstet (1993) 0.86
Measurement of estradiol-17-fatty acid esters in human tissues. J Clin Endocrinol Metab (1992) 0.86
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. Br J Cancer (2011) 0.86
Sequelae of lateral ovarian transposition in unirradiated cervical cancer patients. Gynecol Oncol (1990) 0.85
Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer. Gynecol Oncol (1988) 0.85
Allelic deletion mapping of putative tumor suppressor genes on 17q in sporadic ovarian cancer. J Obstet Gynaecol (Tokyo 1995) (1995) 0.84
Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report. Gynecol Oncol (1996) 0.84
Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy. Int J Radiat Oncol Biol Phys (1998) 0.84
Prognostic value of clinical variables in invasive cervical cancer. Obstet Gynecol (1994) 0.84
hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Br J Cancer (2010) 0.84
Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gynecol Oncol (2004) 0.83
Type 2 herpes simplex virus and vulvar carcinoma in situ. N Engl J Med (1981) 0.83
Pleural and esophageal pressures in the upright body position. J Appl Physiol (1967) 0.83
Ovarian germ cell malignancies: the Yale University experience. Gynecol Oncol (1992) 0.82
Current approaches to diagnosis and treatment of ovarian germ cell malignancies. Curr Opin Obstet Gynecol (1994) 0.82
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). Br J Cancer (2009) 0.82
Evaluation of gynecologic pelvic masses by ultrasound and computed tomography. J Reprod Med (1982) 0.82
Gray-scale ultrasound in 204 proved gynecologic masses: accuracy and specific diagnostic criteria. Radiology (1979) 0.82
Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy. Br J Cancer (2013) 0.82
Bleomycin hydrolase activity and cytotoxicity in human tumors. Cancer Res (1982) 0.82
Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. Gynecol Oncol (1996) 0.81
The incidence and risk factors associated with postoperative delirium in geriatric patients undergoing surgery for suspected gynecologic malignancies. Gynecol Oncol (2008) 0.81
Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC). Gynecol Oncol (1993) 0.81
Are cytosol estrogen and progestin receptors of prognostic significance in the management of epithelial ovarian cancers? Obstet Gynecol (1986) 0.81
Prognostic indicators for poor risk epithelial ovarian carcinoma. Cancer (1994) 0.81
Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer. Cancer (1989) 0.81
A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed müllerian tumors (MMT) of the uterus. Gynecol Oncol (1995) 0.81
Prospective comparison of ultrasound and computed tomography in the evaluation of gynecologic pelvic masses. AJR Am J Roentgenol (1978) 0.81
Gestational trophoblastic neoplasia: diagnosis with Doppler US. Radiology (1987) 0.80
Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: Correlation between biochemical and immunohistochemical methods and survival. Am J Clin Pathol (1990) 0.80
Carcinoma of the cervical stump: comparison of radiation therapy factors, survival and patterns of failure with carcinoma of the intact uterus. Int J Radiat Oncol Biol Phys (1983) 0.80
Adenosarcoma of the uterus: ultrastructural observations. Am J Clin Pathol (1979) 0.80
Intraesophageal pressure gradient in man. J Appl Physiol (1967) 0.80